SURF Surface Oncology Inc.

2.65
0  0%
Previous Close 2.65
Open 2.65
Price To Book 1.07
Market Cap 73,889,303
Shares 27,882,756
Volume 1,836
Short Ratio
Av. Daily Volume 165,109
Stock charts supplied by TradingView

NewsSee all news

  1. Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials

    Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current cash runway into 2022

  2. Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  3. Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures

    CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  4. Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

    Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its ability to promote

  5. Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data presented at SITC meeting November 9, 2019.
SRF231
Hematologic malignancies, solid tumors
Phase 1 initial data due by the end of 2020.
NZV930
Solid tumors
Phase 1 initial data due in 2020.
SRF617
Solid tumors

Latest News

  1. Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials

    Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current cash runway into 2022

  2. Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  3. Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures

    CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  4. Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

    Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its ability to promote

  5. Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  6. Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer's Annual Meeting

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  7. Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City

    Keynote speaker: E. John Wherry, Ph.D., director, Penn Institute for Immunology, University of Pennsylvania, and Co-Director of the Parker Institute for Cancer Immunotherapy at PennPresentations from Surface management

  8. Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc.

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CURLF) Lifshitz & Miller announces investigation into possible securities laws violation in connection with the FDA's warning letter to Curaleaf

  9. Surface Oncology to Present at the Baird 2019 Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  10. Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company's board of directors. Dr. Ibrahim is a medical oncologist currently serving

  11. Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Sunnova Energy on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ:CASA), Greenlane Holdings, Inc. (NASDAQ:GNLN), Surface Oncology, Inc.